AnaptysBio Newsroom

Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80

Futu NewsOct 2 19:31 · Ratings

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaSep 30 20:06

Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $42

Futu NewsSep 26 20:33 · Ratings

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating

Futu NewsSep 26 18:31 · Ratings

J.P. Morgan Reaffirms Their Buy Rating on AnaptysBio (ANAB)

TipRanksSep 26 17:50 · Ratings

AnaptysBio Chief Legal Officer Sells Over $490k in Company Stock

InvestingSep 18 06:52

BTIG Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $55

BTIG analyst Jake Fuller initiates coverage on $AnaptysBio(ANAB.US)$ with a buy rating, and sets the target price at $55.According to TipRanks data, the analyst has a success rate of 48.1% and a

Futu NewsSep 5 22:31 · Ratings

Anaptys Announces Participation in September Investor Conferences

newsfilter.ioAug 29 21:15

Why AnaptysBio Was Such a Healthy Stock This Week

Yahoo FinanceAug 23 19:26

Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM

Seeking AlphaAug 20 03:07

Insiders Buying Yum China And 2 Other Stocks

BenzingaAug 19 21:04

AnaptysBio(ANAB.US) 10% Shareholder Buys US$10 Million in Common Stock

$AnaptysBio(ANAB.US)$ 10% Shareholder EcoR1 Capital, LLC purchased 273.97K shares of common stock on Aug 14, 2024 at an average price of $36.5 for a total value of $10 million.Source: Announcement

Futu NewsAug 17 00:08

AnaptysBio Price Target Raised to $30.00/Share From $20.00 by Truist Securities

Dow JonesAug 15 20:48 · Ratings

Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)

TipRanksAug 15 20:27 · Ratings

Express News | AnaptysBio Inc : Truist Securities Raises Target Price to $30 From $20

BreakingsAug 15 13:22

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target

BenzingaAug 15 02:03 · Ratings

AnaptysBio Analyst Ratings

BenzingaAug 15 02:01 · Ratings

H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright analyst Emily Bodnar maintains $AnaptysBio(ANAB.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 32.9% and

Futu NewsAug 15 00:31 · Ratings

AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline

TipRanksAug 14 23:45 · Ratings

UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday

BenzingaAug 14 22:36